Calcified Tissue International

, Volume 65, Issue 4, pp 292–294

Vitamin D and the D-Hormones, Alfacalcidol and Calcitriol, as Therapeutic Agents for Osteoporotic Populations

  • L. V. Avioli
Editorial

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lindsay R (1988) Role of estrogen in the prevention of osteoporosis. In: Watts NB (ed) Endocrinology and metabolism clinics in North America. WB Saunders, Philadelphia, pp 399–409Google Scholar
  2. 2.
    Watts NB (1988) Treatment of osteoporosis with bisphosphonates. In: Watts NB (ed) Endocrinology and metabolism clinics in North America. WB Saunders, Philadelphia, pp 419–439Google Scholar
  3. 3.
    Avioli LV (1988) Role of calcitonin in the prevention of osteoporosis. In: Watts NG (ed) Endocrinology and metabolism clinics in North America. WB Saunders, Philadelphia, pp 411–418Google Scholar
  4. 4.
    Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647PubMedCrossRefGoogle Scholar
  5. 5.
    Heaney RP, Draper MW (1997) Raloxifene and estrogen: comparative bone-remodeling kinetics. J Clin Endocrinol Metab 82:3425–3429PubMedGoogle Scholar
  6. 6.
    Walters MR (1992) Newly identified actions of the vitamin D endocrine system. Endocr Rev 13:719–764PubMedGoogle Scholar
  7. 7.
    Kinyamu HK, Gallagher JC, Rafferty KA, Balhom KE (1998) Dietary calcium and vitamin D intake in elderly women: effect on serum parathyroid hormone and vitamin D metabolites. Am J Clin Nutr 67:342–348PubMedGoogle Scholar
  8. 8.
    Liu BA, Gordon M, Labranche JM, Murray TM, Vieth R, Shear NH ( 1997) Seasonal prevalence of vitamin D deficiency in institutionalized older adults. JAGS 45:598–603Google Scholar
  9. 9.
    Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777–783PubMedCrossRefGoogle Scholar
  10. 10.
    Kinyamu HK, Gallagher JC, Balhom KE, Petranick KM, Rafferty KA (1997) Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes. Am J Clin Nutr 65: 790–797PubMedGoogle Scholar
  11. 11.
    Jacques PF, Felson DT, Tucker KL, Nahnken B, Wilson PWF, Rosenberg IH, Rush D (1997) Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. Am J Clin Nutr 66:929–936PubMedGoogle Scholar
  12. 12.
    Gloth FM III, Gundberg CM, Hollis BW, Haddad JG Jr, Tobin JD (1995) Vitamin D deficiency in homebound elderly persons. JAMA 274:1683–1686PubMedCrossRefGoogle Scholar
  13. 13.
    Utiger RD (1998) The need for more vitamin D. N Engl J Med 338:828–829PubMedCrossRefGoogle Scholar
  14. 14.
    Villareal DT, Civitelli R, Chines A, Avioli LV (1991) Subclinical vitamin D deficiency in postmenopausal women with low vertebral bone mass. J Clin Endocrinol Metab 72:628–634PubMedCrossRefGoogle Scholar
  15. 15.
    Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637–1642PubMedCrossRefGoogle Scholar
  16. 16.
    Kato S, Sekine K, Matsumoto T, Yoshizawa T (1998) Molecular genetics of vitamin D receptor acting in bone. J Bone Miner Metab 16:65–71CrossRefGoogle Scholar
  17. 17.
    Manolagas SC, Haussler MR, Deftos LJ ( 1980) 1,25-Dihydroxyvitamin D3 receptor-like macromolecule in rat osteogenic sarcoma cell lines. J Biol Chem 255:4414–4417PubMedGoogle Scholar
  18. 18.
    Narbaitz R, Stumpf WE, Sar M, Huang S, DeLuca HF (1983) Autoradiographic localization of target cells for 1,25-dihydroxyvitamin D3 in bones from fetal rats. Calcif Tissue Int 35:177–182PubMedCrossRefGoogle Scholar
  19. 19.
    Yoon K, Rutledge SC, Buenaga RF, Rodan GA (1988) Characterization of the rat osteocalcin gene: stimulation of promoter activity by 1,25-dihydroxyvitamin D3. Biochemistry 27:8521–8526PubMedCrossRefGoogle Scholar
  20. 20.
    Demay MB, Roth DA, Kronenberg HM (1989) Regions of the rat osteocalcin gene which mediate the effect of 1,25-dihydroxyvitamin D3 on gene transcription. J Biol Chem 264: 2279–2282PubMedGoogle Scholar
  21. 21.
    Fraser JD, Otawara Y, Price PA (1988) 1,25-Dihydroxyvitamin D3 stimulates the synthesis of matrix-carboxyglutamic acid protein by osteosarcoma cells. J Biol Chem 263: 911–916PubMedGoogle Scholar
  22. 22.
    Prince CW, Butler WT (1987) 1,25-Dihyrdroxyvitamin D regulates the biosynthesis of osteopontin, a bone-derived, cell attachment protein. Collagen Rel Res 7:305–313CrossRefGoogle Scholar
  23. 23.
    Noda M, Yoon K, Prince CW, Butler WT, Rodan GA (1988) Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type β transforming growth factor. J Biol Chem 263:13916–13921PubMedGoogle Scholar
  24. 24.
    Franceschi RT, James WM, Zerlauth G (1985) 1α,25-Dihydroxyvitamin D specific regulation of Dihydroxyvitamin D specific regulation of growth, morphology, and fibronectin in a human osteosarcoma cell line. J Cell Physiol 123:401–409PubMedCrossRefGoogle Scholar
  25. 25.
    Majeska RJ, Rodan GA (1982) The effect of 1,25(OH)D2D3 on alkaline phosphatase in osteoblastic osteosarcoma cells. J Biol Chem 257:3362–3365PubMedGoogle Scholar
  26. 26.
    Mulkins MA, Manolagas SC, Deftos LJ, Sussman HH (1983) 1,25-Dihydroxyvitamin D3 increases bone alkaline phosphatase enzyme levels in human osteogenic sarcoma cells. J Biol Chem 258:6219–6225PubMedGoogle Scholar
  27. 27.
    Beresford JN, Gallagher JA, Russell RGG (1986) 1,25-Dihydroxyvitamin D3 and human bone-derived cells in vitro: effects on alkaline phosphatase, type I collagen and proliferation. Endocrinology 119:1776–1785PubMedCrossRefGoogle Scholar
  28. 28.
    Wong GL, Luben RA, Cohn DV (1977) 1,25-Dihydroxycholecalciferol and parahormone: effects on isolated osteoclast-like and osteoblast-like cells. Science 197:663–665PubMedCrossRefGoogle Scholar
  29. 29.
    Raisz LG, Maina GM, Gworek SC, Dietrich JW, Canalis E (1977) Hormonal control of bone collagen synthesis in vitro. Inhibitory effect of 1-hydroxylated vitamin D metabolites. Endocrinology 102:731–735CrossRefGoogle Scholar
  30. 30.
    Kream BE, Rowe D, Smith MD, Maher V, Majeska RJ (1986) Hormonal regulation of collagen synthesis in a clonal rat osteosarcoma cell line. Endocrinology 119:1922–1928PubMedCrossRefGoogle Scholar
  31. 31.
    Franceschi RT, Romano PR, Park K (1988) Regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D3 in human osteosarcoma cells. J Biol Chem 263:18938–18945PubMedGoogle Scholar
  32. 32.
    Kurihara N, Ishizuka S, Kiyoki M, Haketa Y, Ikeda K, et al. (1986) Effects of 1,25-dihydroxyvitamin D3 on osteoblastic MC3T3-E1 cells. Endocrinology 118:940–947PubMedCrossRefGoogle Scholar
  33. 33.
    Kelly KA, Gimble JM (1998) 1,25-Dihydroxyvitamin D3 inhibits adipocyte differentiation and gene expression in murine bone marrow stromal cell clones and primary cultures. Endocrinology 139:2622–2628PubMedGoogle Scholar
  34. 34.
    Haussler MR, Whitfield GK, Haussler CA, Hsieh J-C, Thompson PD, Selznick SH, Dominguez CE, Jurutka PW (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349PubMedCrossRefGoogle Scholar
  35. 35.
    Jingushi S, Iwaki A, Higuchi O, Axuma Y, Ohta T, Shida J-I, Izumi T, Ikenoue T, Sugioka Y, Iwamoto Y (1998) Serum 1α,25-dihydroxyvitamin D3 accumulates into the fracture callus during rat femoral fracture healing. Endocrinology 139: 1467–1473PubMedGoogle Scholar
  36. 36.
    Schutze N, Lechner A, Groll C, Siggelkow H, Hufner M, Kohrle J, Jakob F (1998) The human analog of murine cystein-rich protein 16 is a 1α,25-dihydroxyvitamin D3-responsive, immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 139:1761–1770PubMedGoogle Scholar
  37. 37.
    Erben RG, Schutt AM, Miao D, Kollenkirchen U, Haberey M (1997) Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 138:4629–4635PubMedGoogle Scholar
  38. 38.
    Kurihara N, Ishizuka S, Tatsumi J, Arai F, Ikeda K, Roodman GD (1998) 23(S)25(R)-1,25-dihydroxyvitamin D3-lactone, a naturally occurring metabolite of 1,25-dihydroxyvitamin D3, inhibits osteoclast-like cell formation in human bone marrow cultures. J Bone Miner Metab 16:5–10CrossRefGoogle Scholar
  39. 39.
    Aloia JF, Vaswani A, Yeh JF (1988) Calcitriol in the treatment of postmenopausal osteoporosis. Am J Med 84:401–408PubMedCrossRefGoogle Scholar
  40. 40.
    Gallagher JC, Riggs BL (1990) Action of 1,25-dihydroxyvitamin D3 on calcium balance and bone turnover and its effect on vertebral fracture rate. Metabolism 39(4)(suppl 1): 30–34PubMedCrossRefGoogle Scholar
  41. 41.
    Gallagher JC, Riggs BL, Recker RR, Goldgar D (1989) The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 191:287–292PubMedCrossRefGoogle Scholar
  42. 42.
    Caniggia A, Nuti R, Lore F, Martini G, Turchetti V, Righi G (1990) Long-term treatment with calcitriol in postmenopausal osteoporosis. Metabolism 39(4)(suppl 1):43–49PubMedCrossRefGoogle Scholar
  43. 43.
    Dambacher MA, Neff M, Kissling R, Qin L (1998) Highly precise peripheral quantitative computed tomography for the evaluation of bone density, loss of bone density and structures. Drugs Aging 12:15–24PubMedCrossRefGoogle Scholar
  44. 44.
    Barton DH, Hesse HR, Pechet MM, Rizzardo E (1973) A convenient synthesis of 1αvitamin D3. J Am Chem Soc 95: 2748–2749PubMedCrossRefGoogle Scholar
  45. 45.
    Civitelli R (1995) Role of vitamin D metabolites in treatment of osteoporosis. Calcif Tissue Int 57:409–414PubMedCrossRefGoogle Scholar
  46. 46.
    Orimo H, Shiraki M, Hayashi T, Nakamura T (1987) Reduced occurrence of vertebral crush fractures in senile osteoporosis treated with 1α(OH)D3. Bone Miner 3:47–52PubMedGoogle Scholar
  47. 47.
    Shiraki M, Itoh H, Orimo H (1993) The ultra long-term treatment of senile osteoporosis with 1 alpha-hydroxyvitamin D3. Bone Miner 20:223–234PubMedCrossRefGoogle Scholar
  48. 48.
    Caniggia A, Nuti R, Lore F, Martini G, Fredian B, Giovani S (1993) Total body absorptiometry in postmenopausal osteoporosis patients treated with one alpha-hydroxylated vitamin D metabolites. Osteoporosis Int (suppl 1):S181–S185Google Scholar
  49. 49.
    Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N (1994) Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 54:370–376PubMedCrossRefGoogle Scholar
  50. 50.
    Pouilles JM, Tremollieres F, Ribot C (1992) Prevention of postmenopausal bone loss with 1 alpha-hydroxyvitamin D3: a three-year prospective study. Clin Rheumatol 11:1492–1497CrossRefGoogle Scholar
  51. 51.
    Shiraki M (1993) Treatment of osteoporosis with vitamin D3. Osteoporosis Int (suppl 1):S176–S180Google Scholar
  52. 52.
    DeLuca HF (1997) 1,25-dihydroxyvitamin D3 in the pathogenesis and treatment of osteoporosis. Osteoporosis Int 7:S24–S29CrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1999

Authors and Affiliations

  • L. V. Avioli
    • 1
  1. 1.Division of Bone and Mineral DiseasesWashington University School of MedicineSt. LouisUSA

Personalised recommendations